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Abstract
Background: Oncolytic virotherapy is an attractive drug platform of cancer gene therapy, but efficacy and
specificity are important prerequisites for success of such strategies. Previous studies determined that Apoptin is a
p53 independent, bcl-2 insensitive apoptotic protein with the ability to specifically induce apoptosis in tumor cells.
Here, we generated a conditional replication-competent adenovirus (CRCA), designated Ad-hTERT-E1a-Apoptin, and
investigated the effectiveness of the CRCA a gene therapy agent for further clinical trials.
Results: The observation that infection with Ad-hTERT-E1a-Apoptin significantly inhibited growth of the melanoma
cells, protecting normal human epidermal melanocytes from growth inhibition confirmed cancer cell selective
adenoviral replication, growth inhibition, and apoptosis induction of this therapeutic approach. The in vivo assays
performed by using C57BL/6 mice containing established primary or metastatic tumors expanded the in vitro
studies. When treated with Ad-hTERT-E1a-Apoptin, the subcutaneous primary tumor volume reduction was not
only observed in intratumoral injection group but in systemic delivery mice. In the lung metastasis model, Ad-
hTERT-E1a-Apoptin effectively suppressed pulmonary metastatic lesions. Furthermore, treatment of primary and
metastatic models with Ad-hTERT-E1a-Apoptin increased mice survival.
Conclusions: These data further reinforce the previously research showing that an adenovirus expressing Apoptin
is more effective and advocate the potential applications of Ad-hTERT-E1a-Apoptin in the treatment of neoplastic
diseases in future clinical trials.
Background
Despite the many advances achieved in cancer preven-
tion, much improvement is desired for present treat-
ment protocols, including surgery, chemotherapy, and
radiotherapy. These procedures may be effective in the
early stages of disease, but are always palliative and fall
short of eradicating the various malignant subpopula-
tions in neoplastic conditions [1]. The current realities
have highlighted the need for more novel cancer thera-
pies to induce effective responses in clinical trials. Gene
therapy is a promising strategy for patients resistant to
traditional therapies because they target defects in
malignant cells, selectively correcting or eradicating
defective tissues [2]. However, efficacy and specificity
remain major challenges for existing cancer gene ther-
apy [3]. Oncolytic virotherapy is an attractive drug plat-
form of cancer gene therapy consistent with the both
goals [4,5]. The oncolytic viruses exhibit an ability to
replicate selectively in tumor tissues to the exclusion of
normal cells [5]. Furthermore, they can be genetically
manipulated to express multiple cancer cell-specific
therapeutic elements [6]. These characteristics demon-
strate the utility of oncolytic virotherapy in the clinics
and provide the basis for novel approaches to cancer
gene therapy.
Adenovirus-based vectors are the most widely used
platforms in gene delivery [5]. However, non-replicating
adenoviruses are seldom effective in eradicating tumor
cells [7]. Therefore, very high concentrations and multi-
ple administrations are generally needed to produce
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ever, often induce anti-viral immune responses that
result in the neutralization of the viral vectors in subse-
quent immunizations and toxicity to the tissues [8,9].
To circumvent these limitations, conditional replication-
competent adenoviruses (CRCA) have been developed
and are being extensively evaluated; these viruses repli-
cate specifically in tumor cells with subsequent oncolysis
and release of virus progeny to further infect and
destroy neighboring cancer cells [7,10]. Furthermore, it
has been recently suggested that antibodies which neu-
tralize replication-incompetent adenoviruses have lim-
ited effects on the replication-competent adenoviruses
[7,11]. It is therefore reasonable to anticipate that repli-
cation-selective tumor-specific adenoviruses would have
potent effects in cancer gene therapy.
In this study, we constructed an oncolytic adenovirus
using a cancer-specific promoter (human telomerase
reverse transcriptase promoter) and a cancer cell selec-
tive apoptosis-inducing gene (Apoptin) that demon-
strated significant anti-tumor activity toward solid
tumors and metastatic nodules. Telomerase activity is
strikingly higher in about 90% of cancers than in normal
cells, and it has been widely used as a tumor marker.
One of the three subunits of telomerase, human telo-
merase reverse transcriptase (hTERT), is the determi-
n a n to ft h et e l o m e r a s ea c t i v i t ya n di sh i g h l ya c t i v ei n
immortalized cell lines and over 85% of human cancers.
Therefore, its promoter has been used for tumor specific
expression of transgenes. Apoptin, the product of the
chicken anemia virus VP3 gene, shows specificity and
efficiency toward a wide range of transformed and
malignant cells of human origin, including hepatomas,
lymphomas, cholangiocarcinomas, melanomas, and
breast, lung, and colon carcinomas, while sparing non-
transformed primary cells such as fibroblasts, keratino-
cytes, or smooth muscle cells [12-14]. Preliminary stu-
dies have demonstrated the effect of Apoptin inserted in
various vectors on restricting manifold tumors, which
make it attractive for cancer gene therapy [15,16].
In this study, we focused on melanoma, which has
doubled over the past decades and the incidence is
increasing more rapidly than any other cancer [17].
Although melanoma skin cancer can be cured by surgical
excision and efforts have been carried out to develop new
therapies, the prognosis of patients are poor and the 5-
year survival rates range from merely 10% to 50% [17,18].
Moreover, the patients with regional lymphatic or meta-
static disease respond poorly to conventional radiation
and chemotherapy [18]. Here, we describe the construc-
tion of a CRCA, hereafter referred to as Ad-hTERT-E1a-
Apoptin, that can target tumors systemically and selec-
tively induce apoptosis both in vitro and in vivo.W e
showed that infection of melanoma cells with Ad-
hTERT-E1a-Apoptin resulted inas i g n i f i c a n ti n d u c t i o n
of apoptosis and induced growth suppression of mela-
noma cells. To determine whether Ad-hTERT-E1a-
Apoptin can cause tumor regression, we also performed
multiple intratumoral injections or systemic administra-
tions of Ad-hTERT-E1a-Apoptin in subcutaneous homo-
plastic graft or lung metastases models, respectively. Our
findings indicate that Ad-hTERT-E1a-Apoptin represents
a potentially applicable anti-cancer agent for the treat-
ment of primary and metastatic melanoma and may be of
clinical value toward other neoplastic diseases.
Results
Generation of the recombinant adenoviruses
The structures of the recombinant adenoviruses con-
structed for this study are presented in Figure 1A,
including Ad-hTERT-E1a-Apoptin and Ad-CMV-E1a-
Apoptin, in which the E1a gene is under the control of
the hTERT promoter or CMV promoter, respectively,
and Apoptin is controlled by a CMV promoter. We gen-
erated two additional control replicating adenoviruses
without Apoptin, Ad-hTERT-E1a and Ad-CMV-E1a, in
which E1a is expressed by the hTERT or CMV promo-
ters, respectively. The two replication-incompetent ade-
noviruses (lacking the E1a gene) were Ad-hTERT-
Apoptin and Ad-CMV-Apoptin, in which hTERT pro-
moter or CMV promoter drove Apoptin expression,
respectively. An empty adenovirus vector (designated
Ad-mock) was used as control.
Transgene expression and characterization of
recombinant adenoviruses
In the melanoma cell lines (A375 and B16), infection
with Ad-hTERT-E1a-Apoptin, Ad-CMV-E1a-Apoptin,
Ad-hTERT-Apoptin and Ad-CMV-Apoptin resulted in
significant production of Apoptin proteins (15 kDa),
whereas no Apoptin protein was detected after Ad-
hTERT-E1a, Ad-CMV-E1a or Ad-mock infection (Figure
1B and 1C). In the HEM cell line, infection with Ad-
CMV-Apoptin, Ad-hTERT-E1a-Apoptin and Ad-CMV-
E1a-Apoptin, but not Ad-hTERT-Apoptin, Ad-hTERT-
E1a, Ad-CMV-E1a or Ad-mock, produced Apoptin pro-
tein (Figure 1D). A375 or B16 cells infected with Ad-
hTERT-E1a-Apoptin, Ad-CMV-E1a-Apoptin, Ad-
hTERT-E1a and Ad-CMV-E1a produced E1a proteins
(36 kDa); however, cells infected with Ad-hTERT-Apop-
tin, Ad-CMV-Apoptin or Ad-mock did not (Figure 1B
and 1C). Infection of HEM with Ad-CMV-E1a-Apoptin
or Ad-CMV-E1a resulted in E1a production, whereas
infection with Ad-hTERT-E1a-Apoptin, Ad-hTERT-E1a,
Ad-hTERT-Apoptin, Ad-CMV-Apoptin or Ad-mock
resulted in barely detectable E1a expression (Figure 1D).
These results demonstrated that Ad-hTERT-E1a-Apop-
tin had cancer cell-selective replication properties, and
the Apoptin transgene was effectively expressed.
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Ad-hTERT-E1a-Apoptin
As expected, with longer infection times, growth of
A375 or B16 cells infected with Ad-CMV-E1a, Ad-
hTERT-E1a, Ad-CMV-E1a-Apoptin and Ad-hTERT-
E1a-Apoptin were inhibited. However, cells infected
with replication-incompetent adenoviruses (Ad-CMV-
Apoptin, Ad-hTERT-Apoptina n dA d - m o c k )g r a d u a l l y
resumed growth after 2 d. In contrast, the growth of
HEM cells infected only with Ad-CMV-E1a or Ad-
CMV-E1a-Apoptin, in which viral replication is con-
trolled by the CMV promoter, were suppressed. As
shown in Figure 2, the cell viabilities were dependent on
the MOI of the recombinant adenoviruses to some
extent. In A375 and B16 cells, infection with Ad-CMV-
E1a or Ad-hTERT-E1a at an MOI of 10 or 100 induced
cell growth inhibition of 30%-40% and 60%-70% after 4
d, respectively. When infected with 1 MOI or 10 MOI
Figure 1 Schematic of the recombinant adenoviruses and the adenovirus-mediated transgene expression.( A )S c h e m a t i cd i a g r a m
depicting the organization elements in the recombinant adenoviruses. Polyadenylation signal sequence is designated as pA. The indicated cells
were infected with Ad-mock (control) or indicated recombinant viruses at a MOI of 100 for 48 h. Western blot analysis was performed to detect
(B) Apoptin or E1a protein from A375 cells, (C) Apoptin or E1a expression in B16 cells, or (D) Apoptin or E1a expression in HEM cells. Infection of
normal HEM human epidermal melanocytes (D) with Ad-CMV-E1a or Ad-CMV-E1a-Apoptin, but not Ad-hTERT-E1a or Ad-hTERT-E1a-Apoptin,
resulted in production of E1a proteins, whereas in A375 (B) and B16 (C) melanoma cells, infection with all these replication-competent
recombinant adenoviruses generated E1a proteins. In HEM cells (D), infection with Ad-CMV-E1a-Apoptin and Ad-CMV-Apoptin resulted in
Apoptin production, whereas infection with Ad-hTERT-Apoptin or Ad-hTERT-E1a-Apoptin resulted in barely detectable of Apoptin production. In
A375 (B) and B16 (C) cells, infection with Ad-CMV-Apoptin, Ad-hTERT-Apoptin, Ad-CMV-E1a-Apoptin, or Ad-hTERT-E1a-Apoptin generated
significant Apoptin production. 1. Ad-mock; 2. Ad-CMV-Apoptin; 3. Ad-hTERT-Apoptin; 4. Ad-CMV-E1a; 5. Ad-hTERT-E1a; 6. Ad-CMV-E1a-Apoptin; 7.
Ad-hTERT-E1a-Apoptin.
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cell growth was inhibited by 10%-20% and 50%-60%
after 4 d, respectively, and the growth of cells infected
with 100 MOI was almost blocked (70%-80%). However,
in HEM cells, the dose-dependent inhibition was only
observed in the Ad-CMV-E1a and Ad-CMV-E1a-Apop-
tin experimental groups. It is notable that, in A375 and
B16 cells, the replication-competent adenoviruses were
much more potent than the replication-incompetent
adenoviruses in cancer cell suppression. Furthermore,
the growth inhibition of 10 MOI Ad-CMV-E1a-Apoptin
or Ad-hTERT-E1a-Apoptin infected cells were similar
to that of 100 MOI ofAd-CMV-E1a or Ad-hTERT-E1a,
indicating that the adenoviruses with the dual cancer-
specific genes were more effective than the normal repli-
cation-incompetent adenoviruses in inhibiting cell
growth. That is, Ad-hTERT-E1a-Apoptin could replicate
specifically in melanoma cells (A375 and B16) and
restrict the cell growth selectively, and exhibited higher
tumor-specific killing activity than the control viruses.
The interaction of infection time and MOI was complex
and synergistic, and cell viability showed an apparent
dependent relationship on both factors.
Effect of Ad-hTERT-E1a-Apoptin on apoptosis of
melanoma cells
As shown in Figure 3, infection of all recombinant ade-
noviruses resulted in apoptosis of A375 and B16 cells,
whereas in HEM cells, only infection with Ad-CMV-E1a
and Ad-CMV-E1a-Apoptin induced apoptosis. In A375
and B16 cells, infection with the adenoviruses expressing
Apoptin were observed predominantly in a late apopto-
tic stage; however, infection with Ad-CMV-E1a or Ad-
hTERT-E1a were seen in mainly an early apoptotic
stage. In HEM cells, because of the lost of the apoptotic
inducing effect of Apoptin, Ad-CMV-E1a-Apoptin
infected cells presented mainly in an early apoptotic
stage similar to the Ad-CMV-E1a infected cells. These
results indicated that Ad-hTERT-E1a-Apoptin induced
apoptosis in melanoma cells specifically and induced
apoptosis more rapidly than the control viruses.
Ad-hTERT-E1a-Apoptin suppressed subcutaneous primary
tumor growth
The growth kinetics of the tumors following treatment
is shown in Figure 4A. During treatment, compared
with control and Ad-mock-infected groups, the tumors
in the recombinant adenoviruses groups were sup-
pressed after the first three infections. However, soon
after the end of the last injection, the Ad-CMV-Apoptin,
Ad-hTERT-Apoptin, Ad-CMV-E1a and Ad-hTERT-E1a
infected tumors gradually resumed their growth,
whereas most of the Ad-CMV-E1a-Apoptin or Ad-
hTERT-E1a-Apoptin infected tumors grew slowly. Intra-
tumoral injection of Ad-CMV-E1a-Apoptin or Ad-
hTERT-E1a-Apoptin induced a powerful anti-tumor
response. We also evaluated the ability of the recombi-
nant adenoviruses to prolong the survival of the tumor
bearing mice (Figure 4B). For ethical reasons, all animals
in the study were sacrificed by day 60 before the tumors
grew to a volume of 4000 mm
3. Therefore, the true sur-
vival curve of each group of mice was not obtained.
However, it is clear from the mean survival results that
the mice given Ad-CMV-E1a-Apoptin or Ad-hTERT-
E1a-Apoptin showed the longest survival. As shown in
Figure 4B, all saline- and Ad-mock-treated animals died
between 23 and 46 days after intratumoral injection.
After 57 days, all Ad-CMV-E1a-, Ad-hTERT-E1a-, Ad-
CMV-Apoptin-, Ad-hTERT-Apoptin-infected mice died,
whereas 5/6 and 6/6 of Ad-hTERT-E1a-Apoptin- and
Ad-CMV-E1a-Apoptin-infected animals, respectively,
were still alive at that point. The mean survival times
were 30.5 days for saline-treated mice, 33.7 days for Ad-
mock-infected mice, 43.2 days for Ad-CMV-Apoptin-
infected mice, 45.8 days for Ad-hTERT-Apoptin-
infected mice, 47.8 days for Ad-CMV-E1a-infected mice
and 46.5 days for Ad-hTERT-E1a-infected mice. How-
ever, tumor bearing mice infected with Ad-CMV-E1a-
Apoptin and Ad-hTERT-E1a-Apoptin survived much
longer than the other groups and the mean survival was
60 and 57.7 days respectively. The results indicated that
Ad-hTERT-E1a-Apoptin conferred significant survival
benefits in vivo.
Systemic delivery of Ad-hTERT-E1a-Apoptin suppressed
solid melanoma growth
The tumor growth of systemic delivery groups was
observed and measured every four days. As shown in
Figure 4C, compared with saline-treated and Ad-mock-
infected mice, the size impairments of Ad-CMV-Apop-
tin-treated, Ad-hTERT-Apoptin-treated, Ad-CMV-E1a-
treated and Ad-hTERT-E1a-treated tumors were
slightly. However, Ad-CMV-E1a-Apoptin and Ad-
hTERT-E1a-Apoptin had significant inhibitory effects on
the tumors. The tumors infected with Ad-CMV-E1a-
Apoptin or Ad-hTERT-E1a-Apoptin started to show
growth impairment 12 days and the significant differ-
ences among saline-treated, Ad-mock-treated, Ad-CMV-
Apoptin-treated, Ad-hTERT-Apoptin-treated, Ad-CMV-
E1a-treated or Ad-hTERT-E1a-treated and tumors trea-
ted with Ad-CMV-E1a-Apoptin or Ad-hTERT-E1a-
Apoptin were confirmed for the entire days follow-up.
Consistent with the results of the intratumoral injection
experiment, saline-treated and Ad-mock-infected groups
had the worst survival, while infection of Ad-hTERT-
E1a-Apoptin significantly improved the survival (Figure
4D). The mean survival times were 30.167 days for sal-
ine-treated mice, 31.333 days for Ad-mock-infected
mice, 41.333 days for Ad-CMV-Apoptin-infected mice,
44 days for Ad-hTERT-Apoptin-infected mice, 48.167
days for Ad-CMV-E1a-infected mice and 43.667 days
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ing mice infected with Ad-CMV-E1a-Apoptin and Ad-
hTERT-E1a-Apoptin survived much longer than the
other groups and the mean survival was 55 and 60 days
respectively. This observation demonstrated that intrave-
nous injection of Ad-hTERT-E1a-Apoptin could sup-
press the syngeneic graft and effectively improved
survival.
Systemic delivery of Ad-hTERT-E1a-Apoptin reduced
metastatic lung nodules
Mouse survival analysis showed that Ad-hTERT-E1a-
Apoptin or Ad-CMV-E1a-Apoptin treatment signifi-
cantly increased survival of mice in the lung metastasis
model in comparison with the other recombinant ade-
noviruses-infected or saline-treated mice (Figure 5A).
When the experiment was terminated on day 48, 6/10
Figure 2 Assessment of the selective inhibition effect of Ad-hTERT-E1a-Apoptin on melanoma cells. Effects of the different MOIs and
infection times on (A), A375 cell viability, (B) B16 cell viability, and (C), on HEM cell viability. Cells were seeded in 96-well plates (1 × 10
4 cells/
well) one day before cells were infected with various concentrations (1 MOI, 10 MOI, and 100 MOI) of the indicated adenoviruses. Tumor viability
was measured every day over a 4 days period by MTT colorimetric assay and all measurements were performed in triplicate. Data are presented
as mean ± SD. In normal HEM human epidermal melanocytes (C), infection with Ad-CMV-E1a or Ad-CMV-E1a-Apoptin, but not Ad-CMV-Apoptin,
Ad-hTERT-Apoptin, Ad-hTERT-E1a, or Ad-hTERT-E1a-Apoptin, induced growth inhibition. In contrast, in A375 (A) and B16 (B) melanoma cells, Ad-
hTERT-E1a-Apoptin, Ad-hTERT-E1a-Apoptin, Ad-CMV-E1a, and Ad-hTERT-E1a infection resulted in significant growth inhibition. 1. Ad-mock; 2. Ad-
CMV-Apoptin; 3. Ad-hTERT-Apoptin; 4. Ad-CMV-E1a; 5. Ad-hTERT-E1a; 6. Ad-CMV-E1a-Apoptin; 7. Ad-hTERT-E1a-Apoptin.
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Apoptin-infected animals were alive, and the median
survival time between these two groups did not differ
significantly. None of the mice in the other groups were
alive at the end of experiment, and the mean survival
times were 15.7 days for saline-treated mice, 13.3 days
for Ad-mock-infected mice, 29.6 days for Ad-CMV-
Apoptin-infected mice, 29.5 days for Ad-hTERT-
Apoptin-infected mice, 23.1 days for Ad-CMV-E1a-
infected mice and 23.3 days for Ad-hTERT-E1a-infected
mice. As shown by the representative metastasic nodules
in Figure 5B, Ad-hTERT-E1a-Apoptin significantly
decreased tumor burden of the mice. The lungs of mice
infected with Ad-hTERT-E1a-Apoptin had minimal
metastatic nodules, whereas the lungs from control or
treated groups had severe metastasis. Taken together,
Figure 3 Induction of apoptosis selectively in melanoma cells by Ad-hTERT-E1a-Apoptin. (A) Flow cytometry analysis of A375 cells
infected with the recombinant adenoviruses. (B) Fluorescence images of the adenovirus-infected A375 cells stained with Annexin V/PI. (C) Flow
cytometry analysis of B16 cells infected with recombinant adenoviruses. (D) Fluorescence images of the adenovirus-infected B16 cells stained
with Annexin V/PI. (E) Flow cytometry analysis of HEM cells infected with recombinant adenoviruses. (F) Fluorescence images of the adenovirus-
infected HEM cells stained with Annexin V/PI. Representative images of three independent experiments at 100× magnification were used to
show Annexin V binding. Infection with only Ad-CMV-E1a and Ad-CMV-E1A-Apoptin elevated the percentage of apoptotic normal HEM human
epidermal melanocytes (E and F). However, all of the recombinant adenoviruses, except for Ad-mock, resulted in significant apoptosis in A375
(A and B) and B16 (C and D) melanoma cells. 1. Control; 2. Ad-mock; 3. Ad-CMV-Apoptin; 4. Ad-hTERT-Apoptin; 5. Ad-CMV-E1a; 6. Ad-hTERT-E1a;
7. Ad-CMV-E1a-Apoptin; 8. Ad-hTERT-E1a-Apoptin.
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cantly reduced tumor burdens and provided survival
benefits in a lung metastatic cancer model.
Discussion
Despite substantial progress in the development of gene
therapies and traditional treatments in recent years, the
prognosis for many patients with neoplastic diseases
remain poor. Cancer gene therapy based on adeno-
viruses has been extensively studied in pre-clinical and
clinical trials. In particular, CRCA has gained increased
attention for a number of reasons [6,7]. Because the
promoters in these vectors are selective for cancer cells
[6,7], these oncolytic viruses have the ability to replicate
and to spread to adjacent tumor cells [19]. Furthermore,
it has been shown that infection with CRCA generates
anti-tumoral immune responses [20] which can comple-
ment chemo- and radiotherapies [19]. Importantly,
given the proper therapeutic transgenes, CRCA are cap-
able of achieving destruction of primary and distant
tumors [7].
In vitro studies showed that a core region of hTERT
containing two E boxes and several Sp1 sites is sufficient
for the major tumor-selective promoter activity. Many
strategies including CRCA have been developed using
the hTERT core promoter, containing two E boxes and
several Sp1 sites [21], to selectively target tumor cells.
One approach being evaluated uses CNHK300, a repli-
cative adenovirus that targets telomerase positive cancer
cells [22]. A similar replication-competent adenovirus,
Figure 4 Ad-hTERT-E1A-Apoptin suppression of melanoma in the C57BL/6 mice model. (A) Tumor growth kinetics of mice that received
intratumorally injections. (B) Survival curve of mice treated intratumorally. (C) Tumor growth kinetics of mice that received intravenously
injections. (D) Survival curve of mice treated intravenously. The day that the first injection performed was considered as starting day 0. Data
were represented as mean ± SD (A and C). Ad-CMV-E1a-Apoptin or Ad-hTERT-E1a-Apoptin significantly inhibited the growth of tumors in both
introtumoral (A) and systemic (C) delivery groups. Although Ad-CMV-Apoptin, Ad-hTERT-Apoptin, Ad-CMV-E1a or Ad-hTERT-E1a had some
inhibitory effect on tumors in both experimental groups, the antitumor effects of Ad-CMV-Apoptin and Ad-hTERT-Apoptin in systemic delivery
group were marginal (A and C). Furthermore, increased mean survival was also observed in Ad-CMV-E1a-Apoptin or Ad-hTERT-E1a-Apoptin
treated mice in comparison with saline, Ad-mock, Ad-CMV-Apoptin, Ad-hTERT-Apoptin, Ad-CMV-E1a or Ad-hTERT-E1a treated mice in the tumor
models (B and D). 1. Control; 2. Ad-mock; 3. Ad-CMV-Apoptin; 4. Ad-hTERT-Apoptin; 5. Ad-CMV-E1a; 6. Ad-hTERT-E1a; 7. Ad-CMV-E1a-Apoptin; 8.
Ad-hTERT-E1a-Apoptin.
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trol the expression of the adenoviral E4 gene, was cap-
able of tumor selective replication and oncolysis [23].
Analogous results were also obtained in other replicat-
ing adenoviruses, such as Adv-TERTp-E1a [24], hTERT-
Ad [25], and Ad/GT-Bax [26], which appear to be pro-
mising treatment agents for cancer.
The applicability of cancer therapies is not only deter-
mined by their efficiency in eliminating tumor cells;
specificity is an equally important prerequisite [3].
Apoptin has such properties which could potentially
achieve these objectives. Various research groups have
reported that more than 70 analyzed tumor cell lines
were proven to be susceptible to Apoptin whereas it
does not affecting variety of normal, non-transformed
cells such as human endothelial cells, hepatocytes,
hematopoietic stem cells, keratinocytes, or smooth mus-
cle cells [27,28]. On the other hand, Apoptin become
Figure 5 Ad-hTERT-E1a-Apoptin reduction of pulmonary metastatic melanoma and resulting survival benefits. (A) Survival curve. (B)
Representative photographs of lungs from control and treatment groups. The day that the first injection performed was considered as starting
day 0. Saline or Ad-mock treated mice had the worst mean survival and Ad-CMV-E1a-Apoptin or Ad-hTERT-E1a-Apoptin treated mice had the
most improved mean survival (A). Furthermore, both numbers and sizes of lung tumor nodules were reduced in mice treated with Ad-CMV-E1a-
Apoptin or Ad-hTERT-E1a-Apoptin compared with those treated with saline, Ad-mock, Ad-CMV-Apoptin, Ad-hTERT-Apoptin, Ad-CMV-E1a or Ad-
hTERT-E1a (B). 1. Control; 2. Ad-mock; 3. Ad-CMV-Apoptin; 4. Ad-hTERT-Apoptin; 5. Ad-CMV-E1a; 6. Ad-hTERT-E1a; 7. Ad-CMV-E1a-Apoptin; 8. Ad-
hTERT-E1a-Apoptin.
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blasts or UV-irradiated cells with hereditary cancer-
prone syndromes [28,29]. Although, Guelen et al pro-
vided data of toxicity of Apoptin towards non-cancerous
cells, this study proved cell death only in a fetal cell
type and not in other non-transformed cell types
[28,30]. However, the safety of apoptin is underlined by
the fact that continuous expression of Apoptin under
the H2-Kb promoter in transgenic mice does not inter-
fere with lymphocyte development and proliferation
[28,31]. While the mechanism by which Apoptin is able
to distinguish between tumor and normal cells remains
unclear but seems to correlate with its cellular localiza-
tion. Recently, it was shown that Apoptin-induced apop-
tosis essentially depends on abnormal
phosphatidylinositol 3-kinase (PI3-kinase)/Akt activa-
tion, resulting in the activation of the cyclin-dependent
kinase CDK2 [32]. Maddika et al indicated that inhibi-
tors of PI3-kinase or Akt not only inhibited CDK2 acti-
vation but also protected cells from Apoptin-induced
cell death, and Akt-mediated activation of CDK2 was
caused by direct phosphorylation as well as by the phos-
phorylation-induced degradation of its inhibitor p27
(Kip1) [32]. They also identified CDK2 as the principal
kinase that phosphorylates apoptin and is crucially
required for apoptin-induced cell death [32]. Besides the
tumor-selective destruction properties, Apoptin has sev-
eral important features indicating its application as a
novel antitumor agent. One of these characteristics is
the ability of Apoptin to induce tumor-specific apoptosis
independently of p53 [28,33]. Thus, apoptin is similarly
effective in killing tumor cells that are p53-deficient or
either express wildtype or mutant p53 [28,33]. Although
the role of anti-apoptotic molecules such as bcl-2 in
Apoptin-induced apoptosis is still a matter of debate,
another important feature of Apoptin is that in certain
tumor cell lines it mediated cell death is independent of
the Bcl-2 status and is even stimulated by bcl-2 or
insensitive to bcr-Abl and bcl-xl [28,29,34]. The main
controversy as to the role of bcl-2 may focus on the
involvement of Nur77 that can bind to bcl-2 and change
its properties from an anti-apoptotic to a proapoptotic
molecule [28]. Accordingly, the different expression
levels of Nur77 in various cell types might explain the
opposite effects of Bcl-2 on Apoptin induced apoptosis.
Based on these concepts, it therefore reasonable to
anticipate that Apoptin can be used to complement
radiotherapeutic and chemotherapeutic approaches.
More than a quarter (27%) of human gene transfer
protocols registered with the the Recombinant DNA
Advisory Committee (RAC) use adenovirus vectors [35].
The most extensively used first generation human ade-
novirus (hAd) vectors are replication-incompetent
viruses deleted in early region 1 (E1A and E1B) genes.
E1 genes that are expressed rapidly upon adenovirus
penetration into host cells, are responsible for inducing
expression of further viral genes, orchestrating modifica-
tions of cellular gene expression and protein activity to
favor viral replication [36].T w og e n e so ft h i sg r o u p ,
E1A and E1B, act in inactivating tumor suppressor Rb
and p53 genes that are frequently mutated in cancer
cells [7]. Following the generation of E1 deleted hAd
vectors, others hAd vectors (e.g., E1 & E3, E2, E4, E2 &
E4, or E1, E2 & E4-deleted vectors) were constructed
[37]. The products of the E3 gene have been described
as nonessential to viral infection and play a role in mod-
ulation of the host immune response against virus-
infected cells [36]. E2 and E4 genes are involved in mul-
tiple processes, such as transcriptional regulation, DNA
recombination and virus assembly [36]. Various deleted
strategies such as ONYX-015 (dl1520) [38] have been
evaluated to be effective in in vitro and animal models
and led to clinical trials [8,19,39]. Until a fatality case
and other reports of inflammation related to adenovirus
vector, the use of adenovirus-mediated gene transfer in
humans was thought to be fairly benign [35,40]. Because
of the short circulatory half life of naked adenoviruses
and the neutralizing antibodies existed in most adults,
attempts to increase antitumor efficacy through the
administration of high doses of adenovirus vectors can
lead to liver toxicity and immune response [41-43]. For
these reasons, Ad has seen limited clinical use as a sys-
temically administered gene therapy vector. To over-
come the potential increased toxicity and reduced
vector efficacy during the application of adenovirus vec-
tors, it is important that identifying means to evade
innate and pre-existing immunity is a major necessity.
Current strategies include use of alternative adenovirus
serotypes, modification or chimerism of capsid hexon
proteins, generation of hybrid vectors that combine viral
and non-viral elements, coating virus with PEG or simi-
lar polymers, targeting adenovirus to specific organs, tis-
sues or cell types and so on.
In the present study, we describe the generation of a
recombinant adenovirus, Ad-hTERT-E1a-Apoptin, in
which replication was driven by hTERT promoter, that
selectively replicates and specifically induces apoptosis
in tumor cells. When administered to melanoma cells in
vitro, the anti-tumor effects were evident within 24 h; a
single Ad-hTERT-E1a-Apoptin treatment at 100 MOI
or 10 MOI completely inhibited the growth of A375
and B16 cells 4 d later, whereas treatment at 1 MOI
was less effective. In contrast, the growth inhibition was
not observed in HEM cells after treatment with Ad-
hTERT-E1a-Apoptin at any MOI. Furthermore, annexin
V staining showed that the recombinant adenovirus
treated tumors can be divided into two distinct groups:
apoptotic and necrotic cells. Although the infection of
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suppression in A375 and B16 cells, the infection with
Ad-hTERT-E1a-Apoptin remarkably elevated the per-
centage of apoptotic cancer cells. These findings indicate
that the Ad-hTERT-E1a-Apoptin replicates specifically
and induces growth suppression selectively in cancer
cells without harming the normal counterparts.
We also observed anti-tumor activity in vivo in pri-
mary and metastatic tumors, which confirmed and
extended the results of the in vitro studies. Although
the infection of Ad-hTERT-E1a-Apoptin did not lead to
complete elimination of the tumors, effective inhibition
was observed in both primary and metastatic tumor
models. It is plausible that the application of the hTERT
promoter allows the adenovirus replication, viral disper-
sion and transgene expression in any tumor tissues in
the animal, regardless of receiving intratumoral injec-
tions or not. Additionally, apoptotic tumor cells may
trigger dendritic cells to process and present cancer-spe-
cific antigens to responding T lymphocytes, resulting in
a cytotoxic response and inducing apoptosis in the unaf-
fected tumor cells [44]. Ad-hTERT-E1a and Ad-CMV-
E1a also inhibited primary transplantated tumors, but
the effects on metastatic tumors were very limited. In
the in vivo experiments described here, we did not
observe any toxic effects after injection of Ad-hTERT-
E1a-Apoptin. Thus, our data indicate that there is great
potential for improving the safety and efficacy of adeno-
virus vectors for wide application for treatment of neo-
plastic diseases.
Conclusions
Gene therapy with Apoptin offers unique advantages
over current approaches for cancer therapy. The fact
that Apoptin does not need a functional p53 pathway, is
not hindered by the commonly occurring blockage of
apoptosis by bcl-2 or bcr-abl, apparently acts down-
stream of most other factors, and has unparalleled
potency suggests that it will be applicable to a wide
range of tumors. In addition, the CRCA we engineered
induces apoptosis selectively in various cancer cells
without adverse effects on normal cells. Furthermore,
the in vivo and in vitro data of this study show that the
CRCA expressing Apoptin is more effective but also
show that the adenovector dependent on the strong
hTERT promoter does not reduce the efficacy of the
strategy, thus showing an improvement in the global
safety of the CRCA. All these highlights warrant further
evaluation for implementation of this strategy in clinical
trials.
Methods
Cell lines and animals
A375 human malignant melanoma cells, B16 mouse
melanoma cells (syngeneic to C57BL/6 mice) and HEK-
293 human embryonic kidney cells were obtained from
the Committee on Type Culture Collection of Chinese
Academy of Sciences (Shanghai, China). A375 and
HEK-293 cells were cultured in DMEM. B16 cells were
cultured in RPMI 1640. All media (Invitrogen, Beijing,
China) above were supplemented with 10% fetal bovine
serum (FBS; Hyclone, Beijing, China), 100 units/mL
penicillin, and 100 μg/mL streptomycin. HEM human
epidermal melanocytes (primary cells isolated from nor-
mal human neonatal foreskin) were obtained from
ScienCell Research Laboratories (San Diego, CA) and
cultured in MelM medium (ScienCell, Carlsbad, CA)
supplemented with 0.5% FBS and 100 units/mL penicil-
lin, and 100 μg/mL streptomycin. All cell lines were pas-
saged no more than six months after receipt. DNA-
Fingerprinting (monitoring the mutation of human cell
lines), isoenzyme analysis (verify the species of origin),
Scharfe Casy TT system (evaluating cell proliferation)
and Hoechst staining (mycoplasma detection) were used
to characterize cell lines by the supplier. Six- to eight-
week-old female C57BL/6 mice were purchased from
the Experimental Animal Center of the Academy of
Military Medical Sciences (Beijing, China) and housed
in a pathogen-free facility for all experiments following
institutional guidelines.
Recombinant adenoviruses
Recombinant adenoviruses used in this study were pro-
duced with the Adeno-X Expression System (BD Bios-
ciences Clontech) following the manufacturer’s
instructions. Briefly, the transgene cassettes containing
the hTERT core promoter (the 5’ flanking region of the
hTERT gene between positions -283 to -78) driving E1a
and the CMV promoter driving Apoptin were subcloned
into the BD Adeno-X Viral DNA (the adenoviral gen-
ome) via the shuttle vector pShuttle2. Then the infec-
tious adenovirus designated as Ad-hTERT-E1a-Apoptin
was packaged in HEK-293 cells. Similar strategies were
used to generate the other recombinant adenoviruses
designated as Ad-CMV-Apoptin, Ad-hTERT-Apoptin,
Ad-CMV-E1a, Ad-hTERT-E1a and Ad-CMV-E1a-Apop-
tin, and the Ad-Mock was generated using the adeno-
virus backbone only (Figure 1A). The purification and
titration of the amplified virus were performed using
Adeno-X Virus Purification kit (BD Bioscience Clon-
tech) and Adeno-X Rapid titer kit (BD Bioscience Clon-
tech), respectively.
Western blot analysis
Cells were infected with the various adenoviruses at a
multiplicity of infection (MOI) of 100 for 48 h. The
Xiao et al. Molecular Cancer 2010, 9:10
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tern blot as described previously [45]. The primary anti-
bodies were anti-E1a (1:10,000; mouse monoclonal;
Abcam, Cambridge, MA) for E1a detection and anti-
Apoptin (1:1,500; rabbit polyclonal, a kind gift from Mi
Zhiqiang, Jilin University, China) for Apoptin detection,
and the secondary antibodies were horseradish peroxi-
dase(HRP)’conjugated anti-mouse and anti-rabbit IgG
(1:2,500; Abcam), respectively. The bands were visua-
lized with Pierce ECL Western Blotting Substrate
(Pierce, Shanghai, China). Extracts of Ad-mock-infected
cells was used as negative control and detection of
GAPDH was used as an internal control.
Cell viability assay
Cell viability was determined by standard 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT; Sigma, St. Louis, MO) assays as described pre-
viously [45]. Cells were infected with various concentra-
t i o n s( 1M O I ,1 0M O I ,a n d1 0 0M O I )o ft h e
recombinant adenoviruses, and the cell viability was
then measured every day over a 4 d period. The percent
cell death was expressed with respect to control values
using the following formula: [100 × (control cells
-experimental cells)/(control cells)] [46,47].
Flow cytometry analysis
Cells were infected with the recombinant adenoviruses
(100 MOI) for 48 h, trypsinized and washed once with
PBS. The cells (1 × 10
6) were resuspend in binding buf-
fer and stained with FITC-labeled Annexin V (Annexin
V-FITC Apoptosis Detection Kit; BioVision, Mountain
View, California) according to the manufacturer’s proto-
cols. To exclude late apoptotic and necrotic cells, propi-
dium iodide (PI) was added to the FITC-Annexin V-
stained samples. Then, the samples were examined by
flow cytometry (FACScan, Becton Dickinson, Franklin
Lakes, NJ) for apoptosis analysis.
Fluorescence assay
Fluorescent immunostaining was performed on cells
double-stained with FITC-labeled Annexin V and PI fol-
lowing the Annexin V-FITC Apoptosis Detection Kit
(BioVision) manufacturer’s instructions. The cells were
then observed under a fluorescence microscope (BX51;
Olympus) and the images of representative cells were
captured with a CCD camera (DP71; Olympus). Samples
were processed simultaneously, and all images were cap-
tured with the same parameters.
Animal experiments
The in vivo anti-tumor experiments were performed in
three independent models. In the first two models, 1 ×
10
6 B16 cells were implanted subcutaneously into the
right flank of C57BL/6 mice. Once the tumor size
reached 50 to 100 mm
3,m i c ew e r er a n d o m l ya s s i g n e d
to 8 treatment groups (6 mice per group). After estab-
lishment of the tumors, the mice of the first model
received intratumoral injections of various recombinant
adenoviruses at a dose of 1 × 10
9 plaque-forming units
(pfu) in 50 μl of saline, and the control group received
50 μl of saline alone. In the second model, the injections
were administered via the tail vein. All injections were
given every two days for the first week (day 6, 8 and 10
after implantation) and once weekly for two more weeks
(day 17 and 21 after implantation). Tumor size was
measured using calipers every four days and calculated
with a formula of [0.52(smallest diameter )
2(largest dia-
meter )] [45,48]. In the third model, 1 × 10
6 B16 cells
were administered via tail vein. Six days after implanta-
tion, the mice were treated according to the injection
protocol of the second model. During the tumor study,
a l la n i m a l sw e r em o n i t o r e dd a i l ya n ds a c r i f i c e da tt h e
end of the experiment.
Statistical analysis
The statistical significance of differences was done using
one-way ANOVA and statistical significance was
accepted as P < 0.05. Log rank tests were used for survi-
val analysis. Data from all animals are represented in
the Kaplan-Meier plots.
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